CRVS — Corvus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $220.76m
- $168.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.78 | ||
| Price to Tang. Book | 6.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.22% | ||
| Return on Equity | -174.85% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 2.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Directors
- Richard Miller CHM (70)
- Leiv Lea CFO (67)
- William Jones SVP (56)
- Mehrdad Mobasher SVP (48)
- Ian Clark IND (60)
- Elisha Gould IND (64)
- Linda Grais IND (64)
- Edith Mitchell IND (73)
- Scott Morrison IND (63)
- Peter Thompson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 27th, 2014
- Public Since
- March 23rd, 2016
- No. of Shareholders
- 16
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 68,135,796
- Address
- 863 Mitten Rd Ste 102, BURLINGAME, 94010-1311
- Web
- https://www.corvuspharma.com/
- Phone
- +1 6509004520
- Contact
- Leiv Lea
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CRVS
Corvus Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Corvus Pharmaceuticals Inc Earnings Release
Similar to CRVS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Corvus Pharmaceuticals share price?
As of Today at 20:04 UTC, shares in Corvus Pharmaceuticals are trading at $3.24. This share price information is delayed by 15 minutes.
How has the Corvus Pharmaceuticals share price performed this year?
Shares in Corvus Pharmaceuticals last closed at $3.24 and the price had moved by +138.24% over the past 365 days. In terms of relative price strength the Corvus Pharmaceuticals share price has outperformed the S&P500 Index by +124.01% over the past year.
What are the analyst and broker recommendations for Corvus Pharmaceuticals?
The overall consensus recommendation for Corvus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Corvus Pharmaceuticals dividend yield?
Corvus Pharmaceuticals does not currently pay a dividend.
Does Corvus Pharmaceuticals pay a dividend?
Corvus Pharmaceuticals does not currently pay a dividend.
When does Corvus Pharmaceuticals next pay dividends?
Corvus Pharmaceuticals does not currently pay a dividend.
How do I buy Corvus Pharmaceuticals shares?
To buy shares in Corvus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Corvus Pharmaceuticals?
As of the previous close price of $3.24, shares in Corvus Pharmaceuticals had a market capitalisation of $220.76m.
Where are Corvus Pharmaceuticals shares listed?
Here are the trading details for Corvus Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CRVS
What kind of share is Corvus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Corvus Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Corvus Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Corvus Pharmaceuticals is $15.00. That is 362.96% above the last closing price of $3.24.
Analysts covering Corvus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
Find out moreWhat is the trend in the Corvus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Corvus Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -50.2%.
As of the last closing price of $3.24, shares in Corvus Pharmaceuticals were trading -36.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Corvus Pharmaceuticals PE Ratio?
The Corvus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Corvus Pharmaceuticals?
Corvus Pharmaceuticals' management team is headed by:
- Richard Miller - CHM
- Leiv Lea - CFO
- William Jones - SVP
- Mehrdad Mobasher - SVP
- Ian Clark - IND
- Elisha Gould - IND
- Linda Grais - IND
- Edith Mitchell - IND
- Scott Morrison - IND
- Peter Thompson - IND